Numinus Wellness Inc. is a Canada-based health care company. The Company is creating solutions centered around developing and supporting the safe, evidence-based accessible use of psychedelic-assisted psychotherapies. The Company is engaged in the integrative health industries and operates through three divisions: Numinus Biosciences, Numinus Health and Mindspace Psychology Services. Numinus Bioscience provides services, including cultivation, analytical testing, product research and development, and ancillary services under its Health Canada licenses. The testing license allows the Company to test and analyze cannabis products from licensed producers, and the dealer’s license allows the Company to test, possess, buy and sell methylenedioxymethamphetamine (MDMA), psilocybin, psilocin, dimethyltryptamine (DMT) and mescaline. Numinus Health and Mindspace Psychology Services operates centers located in Vancouver, British Columbia and Montreal, Quebec.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.